CAR T-Cell Therapy KTE-X19 Makes Waves in Relapsed/Refractory MCL
Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.
Expert Shares Insight on Utility of Immunotherapy and Targeted Agents Across NSCLC
Gregory A. Otterson, MD, discusses the utility of immunotherapy in squamous non–small cell lung cancer and targeted the evolution of targeted therapy in biomarker-driven disease.
Relapsed/Refractory ALL Paradigm Rapidly Evolving With Novel Agents
Jonathan E. Brammer, MD, discusses the role of minimal residual disease and transplant in acute lymphoblastic leukemia, as well as the introduction of CAR T-cell therapy and other novel agents to the armamentarium.
Wang Highlights Encouraging CAR T-Cell Activity in MCL
Michael Wang, MD, discusses the ZUMA-2 trial and the potential impact of CAR T-cell therapy on the treatment paradigm in mantle cell lymphoma.
Exploration With Blinatumomab and CAR T-Cell Therapy Continues in ALL
Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.
Real-World Analysis Shows Cost-Reducing Benefit With CAR-T in Relapsed DLBCL
Karl M. Kilgore, PhD, discusses how results of real-world analysis may impact the utilization of CAR T-cell therapy for older patients with relapsed/refractory diffuse large B-cell lymphoma.
"Fast and Furious" Development of Novel Approaches Changes Face of Myeloma Treatment
In an era of personalized medicine in oncology, monoclonal antibodies, bispecific T-cell engagers, and CAR T-cell therapies are revolutionizing patient outcomes in multiple myeloma.
Prognostic and Predictive Assays Guide Therapy Decisions in Breast Cancer
Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.
CAR T Cells Could Revolutionize RCC Treatment
Wayne A. Marasco, MD, PhD, discusses the intricacy of engineering CAR T cells and the early data he has observed with CAR T-cell therapy in renal cell carcinoma.